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Abstract 
Background: Procalcitonin (PCT) is a well‑known prognostic marker after elective cardiac surgery. However, the 
impact of elevated PCT in patients with an initially uneventful postoperative course is still unclear. The aim of this 
study was to evaluate PCT levels as a prognostic tool for delayed complications after elective cardiac surgery.
Methods: A prospective study was performed in 751 patients with an apparently uneventful postoperative course 
within the first 24 h after elective cardiac surgery. Serum PCT concentration was taken the morning after surgery. All 
patients were screened for the occurrence of delayed complications. Delayed complications were defined by in‑
hospital death, intensive care unit readmission, or prolonged length of hospital stay (>12 days). Odds ratios (OR) [with 
95% confidence interval (CI)] were calculated by logistic regression analyses and adjusted for confounders. Predictive 
capacity of PCT for delayed complications was calculated by ROC analyses. The cutoff value of PCT was derived from 
the Youden Index calculation.
Results: Among 751 patients with an initially uneventful postoperative course, 117 patients developed delayed 
complications. Serum PCT levels the first postoperative day were significantly higher in these 117 patients (8.9 ng/ml) 
compared to the remaining 634 (0.9 ng/ml; p < 0.001). ROC analyses showed that PCT had a high accuracy to predict 
delayed complications (optimal cutoff value of 2.95 ng/ml, AUC of 0.90, sensitivity 73% and specificity 97%). Patients 
with PCT levels above 2.95 ng/ml the first postoperative day had a highly increased risk of delayed complications 
(adjusted OR, 110.2; 95% CI 51.5–235.5; p < 0.001).
Conclusions: A single measurement of PCT seems to be a useful tool to identify patients at risk of delayed complica‑
tions despite an initially uneventful postoperative course.
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Background
Procalcitonin (PCT) is a well-known marker after elec-
tive cardiac surgery [1–7]. It is a 116-amino acid peptide 
secreted from thyroid parafollicular cells as the precursor 
of calcitonin [8]. Regarding inflammatory response, PCT 
is synthesized in nearly all organs like liver, lung, kid-
ney, intestine and almost all other tissues throughout the 
body [9, 10]. The production of PCT can be induced by 
endotoxin of gram-negative bacteria or by proinflamma-
tory cytokines (e.g., IL-1 and IL-6 or TNF-α) [8].
High serum PCT has been described in patients with 
systemic infection [11], strongly correlating with the 
extent and severity of bacterial infections and in case of 
systemic inflammatory response [12, 13].
The use of cardiopulmonary bypass leads to various 
degrees of a systemic inflammatory response syndrome 
associated with an increase of PCT levels within the first 
24  h postoperatively [7, 13, 14]. Cardiac patients with 
increased serum levels of PCT have been found to be 
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related to the development of complications after surgery 
[1–7, 15]. However, these studies were not focused on 
patients with an initially uneventful postoperative course. 
If the initially postoperative course was uneventful, the 
elevated PCT levels were not included in the decision-
making process for further therapy concepts. This was 
due to the fact that the predictive value of elevated PCT 
levels on the first postoperative in patients with initially 
uneventful postoperative course is still unknown. How-
ever, if these patients developed delayed complications 
with the need for ICU readmission, an extension of hos-
pital stay with worse outcome was expected [16, 17].
In this prospective cohort study, we analyzed the pre-
dictive power of a single serum procalcitonin measure-
ment in identifying patients after elective cardiac surgery 
at risk of delayed complications despite an initially une-
ventful postoperative course. Although a single value of 
PCT is described to have rather a discriminative impact 
than prognostic significance [18], in the postoperative 
setting, only a single measurement would be helpful.
Methods
Study design and setting
The study was designed as a prospective cohort study and 
approved by the local ethics committee (Landesärztekam-
mer des Saarlandes; Ref. ID: 199/09). All patients sched-
uled for cardiac surgery between January 2010 and March 
2011 at our center were screened for participation. The 
inclusion criterion was elective cardiac surgery with cardi-
opulmonary bypass, having an initially uneventful postop-
erative course. Exclusion criteria comprised: age <18 years, 
refusal to participate, planned off-pump surgery, urgent 
cardiac surgery, insufficient knowledge of the German lan-
guage or all-cause complications in the immediate post-
operative course. Written informed consent was obtained 
from all patients meeting the above-mentioned criteria 
and being included in this study. Patient demographics 
and perioperative data were entered into a computerized 
data bank in addition to the medical record chart.
Study population
In our center, all elective patients with initially uneventful 
postoperative course were admitted to our intensive care 
unit for extubation. If the patients could be extubated 
within 9 h of surgery and showed an apparently unevent-
ful postoperative course, the patients were discharged 
from our intensive care unit at latest the morning after 
surgery. The initially uneventful postoperative course is 
defined as: less than 24  h within an intensive care unit 
(ICU), the patients were in a clinically stable hemody-
namic and respiratory condition, they did not show signs 
of stroke or bleeding necessitating surgery intervention 
and were without acute renal failure after the first night 
of surgery (defined by AKIN criteria) [19]. Delayed com-
plications were defined as: complications occurring after 
initially uneventful postoperative course resulting in in-
hospital death, intensive care unit readmission or the 
need for prolonged length of hospital stay (LOS) of more 
than 12 days. Medical reasons for delayed complications 
were mainly neurological complications, respiratory fail-
ure, cardiac arrhythmia, infections or acute kidney injury 
with need for dialysis. We compared patients with and 
without delayed complications.
Endpoints
The primary endpoint of the study was declared as “com-
bined adverse outcome” in which this was defined as the 
occurrence of any delayed complication after initially 
uneventful postoperative course in patients undergoing 
elective cardiac surgery. The secondary endpoint was 
all-cause mortality during the postoperative observation 
period.
PCT measurement
Blood was sampled for inflammatory markers (procalci-
tonin, leukocytes and C-reactive protein) the day before 
surgery from a peripheral vein and on the first postop-
erative morning from a central venous catheter (8–16 h 
postoperatively). PCT concentration was determined in 
the hospital laboratory using the Elecsys BRAHMS PCT 
automated electrochemiluminescence assay (BRAHMS 
AG, Hennigsdorf, Germany) utilizing a cobas® 8000 
modular analyzer (Roche Diagnostics, Basel, Switzer-
land) according to the manufacturer’s instructions. The 
functional assay sensitivity (lowest quantifiable concen-
tration with a between-run imprecision of <20%) met the 
Roche Diagnostics specification of 0.06 ng/ml PCT. The 
between-day coefficients of variation for the PCT analy-
ses were found in Elecsys BRAHMS PCT controls with 
1.75% for 0.49 ng/ml and 1.62% for 9.6 ng/ml precision.
To date, C-reactive protein and leukocytes are routinely 
used as the marker for infection or inflammation in our 
center. In contrast, PCT was not routinely determined 
during the study period. Therefore, PCT levels had no 
influence on the clinical treatment of patients. For more 
than 200 patients, levels of PCT were determined only 
subsequently after discharge.
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation. Categorical variables are presented as a per-
centage unless otherwise stated. Chi-squared tests were 
performed for the comparison of frequencies between 
groups. For continuous variables, the differences between 
groups were compared using Student’s t tests. If values 
did not show normal distribution, Mann–Whitney U test 
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was used. Two-sided p values of <0.05 were considered 
statistically significant.
Different receiver operating characteristic (ROC) 
curves were constructed to evaluate the predictive power 
of inflammatory markers for the occurrence of delayed 
complications. The Youden Index was used to calculate 
optimal cutoff points for inflammatory markers in pre-
diction of delayed complications.
To determine the risk of elevated postoperative serum 
PCT for delayed complications, odds ratios were calculated 
by logistic regression analyses with 95% confidence intervals 
(CI). Two additional models were calculated adjusting for 
potential confounders. Potential confounders in model one 
were: preoperative age, glomerular filtration rates (eGFR, 
calculated by CKD-EPI formula) and EuroSCORE 2. In the 
second model, we further adjusted for: preoperative C-reac-
tive protein (CRP), pulmonary hypertension, valve surgery, 
combination surgery, redo coronary artery bypass grafting 
(CABG) and/or cardiac valve surgery and cardiopulmonary 
bypass (CPB) time since these factors showed differences 
between patients developing delayed complications and those 
who did not. To account for possible collinearity in multiple 
regressions, Pearson’s or Spearman’s correlation coefficients 
were calculated. Variables with a positive or negative bivariate 
correlation exceeding +0.3 or less than −0.3 were evaluated 
for interactions. The goodness of fit was assessed by Hosmer–
Lemeshow tests. Data analysis was performed using SPSS 
Statistics 19™ (IBM, Ehningen, Germany).
Results
Study population
During the study period, 1272 patients underwent car-
diac surgery with extracorporeal circulation. Of these, 
407 patients did not meet inclusion criteria due to urgent 
or emergency surgery or refused participation. In total, 
114 patients were excluded due to severe postopera-
tive complications occurring in the immediate postop-
erative course. The final study population thus included 
751 patients with an initially uneventful postoperative 
course. Of these 117 patients developed delayed com-
plications after discharge from the intensive care unit 
(Fig. 1). Patients developing delayed complications were 
generally: older, had poorer preoperative renal function, 
a higher EuroSCORE 2 and lower left-ventricular ejec-
tion fraction. Operation time and CBP time were longer, 
and the portion of combined surgery was higher in this 
group. The outcome worsened in patients developing 
delayed complications compared without. ICU read-
mission was observed in 51 of 117 patients developing 
delayed complications. They had a significantly increased 
mechanical ventilation time, prolonged length of stay in 
the intensive care unit and hospital, as well as a higher 
hospital mortality (Table 1).  
Serum procalcitonin level and delayed complications
Comparing patients with and without delayed complica-
tions, PCT levels were significantly different the morn-
ing after surgical intervention (8.6 ± 13.5 and 0.9 ± 1.2, 
respectively; p < 0.001; Table 2; Fig. 2a).
ROC analyses of postoperative PCT serum levels and 
the occurrence of any delayed complication revealed an 
AUC of 0.90 with an optimal cutoff value of 2.95 ng/ml 
(sensitivity: 0.73, specificity: 0.97; Fig. 2b).
Looking in detail at the occurrence of different compli-
cations, mean PCT levels on the first postoperative day 
varied between 4.4 ± 4.8 and 12.8 ± 17.3 ng/ml. Thereby, 
the corresponding predictive capacity of PCT levels 
showed an AUC between 0.75 and 0.90 (Table 3).
After multivariable analysis, patients with PCT levels 
above the cutoff value of 2.95 ng/ml the first postopera-
tive day had a 66 times higher risk of developing delayed 
complications compared to those with PCT levels below 
this threshold. Even after adjustment for potential con-
founders, a serum PCT level >2.95  ng/ml remained 
an independent and strong risk factor (adjusted 2 OR: 
110.16, 95% CI 51.53–235.52; Table  4). Goodness of fit 
for each adjusted model was assessed by Hosmer–Leme-
show tests and was not statistically significant.
Preoperative and postoperative parameters 
of inflammation
Preoperative levels of CRP and PCT were different in 
patients developing delayed complications and those 
who did not (CRP: 7.4 ± 16.8 vs. 16.2 ± 33.7, p = 0.001; 
PCT: 0.03  ±  0.14 vs. 0.09  ±  0.28, p  <  0.001). However, 
Fig. 1 Flowchart
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leukocytes were similar between both groups (leukocytes: 
7.4  ±  3.9 vs. 7.8  ±  2.5, p  =  0.12). All patients showed 
postoperatively a comparable rise of CRP and leukocytes 
(Table 2). With respect to the postoperative CRP levels or 
the number of leukocytes, it was not possible to distin-
guish patients who would develop delayed complications 
and those who would not. ROC analyses showed that 
elevated postoperative PCT serum levels had the highest 
discrimination to predict delayed complication compared 
with CRP and leukocytes (Table  5). Postoperative PCT 
serum levels showed the highest positive and negative 
predictive value compared with all other inflammatory 
markers. 
Discussion
The most impressive finding of this study is that a single 
postoperative measurement of procalcitonin (PCT) lev-
els predicts delayed complications in patients undergoing 
elective cardiac surgery despite an apparently unevent-
ful postoperative course. The morning after surgical 
intervention, PCT levels were significantly increased in 
patients with delayed complications in univariate and 
multivariate analysis. ROC analyses revealed that 
increased PCT levels had a highly predictive accuracy to 
detect these delayed complications.
The use of cardiopulmonary bypass (CPB) leads to 
varying degrees of tissue inflammation and cytokine 
Table 1 Baseline characteristics and in-hospital outcome
Data are expressed as mean ± standard deviation
Statistically significant p values are in italics (p < 0.05)
eGFR (CKD-EPI) glomerular filtration rates, calculated by CKD-EPI-formula (Chronic Kidney Disease Epidemiology Collaboration). NYHA class New York Heart Association 
functional classification, COPD chronic obstructive pulmonary disease, CABG surgery coronary artery bypass grafting surgery, CPB time cardiopulmonary bypass time, 
ICU intensive care unit
Characteristic Patients without delayed  
complications (n = 634)





Male 445 (70) 74 (65) 0.16
Age (years) 61.5 ± 15.2 67.7 ± 11.6 <0.001
Weight (kg) 82.6 ± 15.1 81.5 ± 81.5 0.26
Size (cm) 173 ± 9.6 171 ± 9.0 0.11
Body mass index (kg/m2) 27.7 ± 4.5 27.7 ± 4.9 0.76
eGFR (CKD‑EPI) 86.7 ± 33.8 70.0 ± 32.4 <0.001
EuroSCORE 2 4.9 ± 5.6 8.0 ± 6.9 <0.001
Ejection fraction (%) 60.3 ± 13.9 55.4 ± 16.2 0.009
NYHA class 2.9 ± 0.5 2.9 ± 0.6 0.39
Comorbidity
Coronary artery disease (n) (%) 258 (41) 57 (49) 0.13
Pulmonary hypertension (n) (%) 122 (19) 34 (29) 0.019
COPD (n) (%) 34 (5) 10 (9) 0.20
Status past stroke (n) (%) 23 (4) 4 (4) 1
Insulin‑dependent diabetic (n) (%) 27 (4) 10 (9) 0.061
Intraoperative
Procedure type (n) (%)
CABG surgery 228 (36) 49 (42) 0.25
Valve surgery 442 (70) 92 (79) 0.059
Combination surgery 183 (29) 55 (47) <0.001
Redo CABG and/or valve 68 (11) 12 (10) 1
Operation time (min) 159 ± 44.5 189 ± 63.8 <0.001
CPB time (min) 77 ± 28.6 100 ± 42.1 <0.001
Outcome
Mech. ventilated (h) (min–max) 5.0 ± 2.1 35.4 ± 102 <0.001
Length of stay (days)
In ICU (days) (min–max) 0.9 ± 0.3 3.1 ± 6.0 <0.001
In hospital (days) (min–max) 9.3 ± 1.6 20.1 ± 11.3 <0.001
Hospital mortality (%) 0 (0) 4 (3) 0.001
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liberation [20] because it triggers a systemic inflamma-
tory response syndrome with raising PCT levels during 
the first 24 h after surgery [13, 21]. PCT peak levels seem 
to be associated with different types of surgery [21]. It is 
well known that elevated serum PCT has been described 
as an independent predictor of hospital all-cause mortal-
ity within the intensive care setting [22] and correlates 
with poor outcome after cardiac surgery [3, 4, 6, 7, 23]. 
However, the meaning of elevated PCT levels in patients 
with an uneventful postoperative course is still unclear.
If patients with elevated PCT levels are at higher risk 
to develop delayed complications despite an initially 
uneventful postoperative course, PCT could be involved 
in the decision-making process for further therapy con-
cepts. Delayed complications resulting in readmission to 
intensive care unit lead to prolonged hospital stay and 
increased mortality [16, 17]. That was also seen in our 
patients with delayed complications. Therefore, early 
identification of patients at risk of delayed complications 
is needed.
Cases with delayed complications mostly result in 
longer hospital stay. However, a variety of factors can 
influence LOS with significant differences existing 
between the health systems of different nations. The 
Table 2 Preoperative and postoperative serum levels of C-reactive protein, leukocytes and procalcitonin (PCT)
Data are expressed as mean ± standard deviation
Statistically significant p values are in italics (p < 0.05)
Characteristic Patients without delayed  
complications (n = 634)





PCT (ng/ml) (min–max); normal: <0.5 ng/ml 0.03 ± 0.14 0.09 ± 0.28 <0.001
Leukocytes (×109/l) (min–max) 7.4 ± 3.9 7.8 ± 2.5 0.12
C‑reactive protein (mg/l) (min–max); normal: <5 mg/l 7.4 ± 16.8 16.2 ± 33.7 0.001
Postoperative
PCT [ng/ml] (min–max); normal: <0.5 ng/ml 0.9 ± 1.2 8.6 ± 13.5 <0.001
Leukocytes (×109/l) (min–max) 11.3 ± 4.3 12.6 ± 4.2 <0.001
C‑reactive protein (mg/l) (min–max); normal: <5 mg/l 70.0 ± 29.7 74.8 ± 33.7 0.24
Fig. 2 Postoperative serum levels of procalcitonin and ROC curve analysis
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current study was conducted in Germany. Patients are 
normally admitted to hospital the day before surgery 
and generally discharged only when home situation is 
ensured or direct transfer to a rehabilitation facility is 
possible. These factors can affect discharge planning. In 
our center, we aim for a total LOS < 10 days. A study by 
Kiessling and colleagues within Germany found a mean 
LOS of 10.3 ± 2.5 days in patients with a successful fast 
track and a mean LOS of 16.5  ±  16.3  days when fast-
track failure occurred [17]. We chose LOS  >  12  days as 
cutoff value for prolonged stay as we feel that this would 
take into account the aforementioned factors. Moreover, 
in this way it would be possible to incorporate clinically 
relevant delayed complications accounting for a longer 
hospital stay.
In order to evaluate PCT as a marker to identify 
patients at risk of delayed complications, we selected 
only patients with an initially uneventful postoperative 
course and used logistic regression analysis adjusting 
for confounders. After adjustment of confounders, PCT 
remained an independent predictor.
ROC curve analysis of postoperative PCT levels 
revealed a highly predictive value for the occurrence 
of any delayed complications; the prediction of a spe-
cific complication regarding the various complications 
encountered was not possible. In line with our results, 
previous studies found that PCT levels revealed a highly 
predictive value for the occurrence of complications after 
cardiac surgery [3–5, 24, 25]. Nevertheless, PCT levels 
were not found to be specific for an explicit complica-
tion, but predict various complications such as SIRS, 
Table 3 Reasons for delayed complications and predictive accuracy of procalcitonin (PCT) for these complications
In some patients more than one complication occurred. Data are expressed as mean ± standard deviation
AUC area under the curve
(n = 751) Predictive accuracy of PCT for delayed complications
Incidence  
(n)






Respiratory failure 16 7.6 ± 10.1 0.90 0.85–0.95 <0.001 >3.1 81 90
Cardiac arrhythmia 40 6.0 ± 7.3 0.90 0.84–0.95 <0.001 >2.3 90 87
Other complications 21 12.8 ± 17.3 0.89 0.79–0.99 <0.001 >3.0 86 89
Infection
Instability or sepsis 44 11.5 ± 17.8 0.89 0.82–0.95 <0.001 >2.3 86 87
SIRS/sepsis 29 4.4 ± 4.8 0.75 0.62–0.87 <0.001 >1.3 74 71
Table 4 Serum procalcitonin levels on the first postopera-
tive day as predictor for delayed complications
Data are expressed as odds ratios with 95% confidence intervals (CI). Potential 
confounders in model one (adjusted 1) were: preoperative age, glomerular 
filtration rates and EuroSCORE 2. In the second model (adjusted 2), we further 
adjusted for: preoperative C-reactive protein, pulmonary hypertension, valve 
surgery, combination surgery, redo coronary artery bypass grafting and/or 
cardiac valve surgery and cardiopulmonary bypass time
Postoperative cutoff PCT > 2.95 ng/ml and risk 
of delayed complications
Odds ratio 95% CI χ2 (p value)
Crude 66.38 36.73–119.96 265.67 (<0.001)
Adjusted 1 89.76 45.19–178.30 299.22 (<0.001)
Adjusted 2 110.16 51.53–235.52 328.79 (<0.001)
Table 5 Data are expressed as AUC (area under the curve) with 95% confidence interval (CI)
Different receiver operating characteristic (ROC) curves were constructed to evaluate the predictive power for delayed complications
PPV the positive predictive value, NPV the negative predictive
ROC analysis to predict delayed complications (n = 751)
AUC 95% CI p value Cutoff Likelihood ratio Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Preoperative
Procalcitonin (ng/ml) 0.58 0.52–0.64 0.007 >0.05 2.32 28 88 30 87
Leukocytes (x109/l) 0.57 0.52–0.63 0.02 >9.3 1.97 27 86 27 87
C‑reactive protein (mg/l) 0.60 0.54–0.65 <0.001 >11.6 2.07 27 87 28 87
Postoperative
Procalcitonin (ng/ml) 0.90 0.87–0.94 <0.001 >2.95 21.83 73 97 82 95
Leukocytes (×109/l) 0.62 0.56–0.67 <0.001 >13.7 1.82 35 81 25 87
C‑reactive protein (mg/l) 0.53 0.48–0.59 0.24 >46.4 1.06 85 21 16 88
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sepsis, infection without circulatory instability, myocar-
dial infarction and respiratory failure [3–5, 24–26].
The use of cardiopulmonary bypass is associated with an 
increase of PCT and CRP levels [7, 14]. Our results con-
firm this postoperative increase in inflammatory mark-
ers. All three markers, PCT, CRP and leukocyte, were 
increased postoperatively. However, patients at risk of 
delayed complications could only be identified by means 
of elevated PCT levels. The failure of CRP as a prognostic 
marker after cardiac surgery is in line with previous stud-
ies [5, 14]. White cell count showed a significant differ-
ence comparing patients with delayed complications and 
all remaining patients. However, in clinical practice this 
small difference is not considered as “different.”
Postoperative delayed complications would be depend-
ent on many factors. However, this raises a crucial ques-
tion: What is the reason for different increase of PCT in 
patients? As shown in Table 1, comorbidity and intraop-
erative parameters were different and could explain more 
postoperative complications. However, after surgery 
the patients showed no clinical signs of complications. 
Nevertheless, it is known that increased PCT levels are 
associated with many inflammatory diseases (e.g., blood 
stream infection, pneumonia, renal failure or heart fail-
ure) [11, 27–30], all known to possibly occur after car-
diac surgery. It can be summarized that it seems that 
increased PCT levels are associated with worse global 
health condition. We hypothesize that the raise of PCT 
after surgery is an early warning signal of upcoming com-
plications associated with proinflammatory states.
Regarding our results, monitoring postoperative PCT 
levels could be a helpful tool to predict likelihood of 
delayed complications independently of the patient’s clin-
ical appearance the first postoperative day. That can be 
easily integrated into clinical practice and help decision-
making processes for planning postoperative monitoring. 
We assume that the focus to see every patient and ther-
apy more individually could be helpful to improve patient 
outcome.
Limitations
Our major limitation is that we built our models from 
a single population. Due to the study design, physicians 
and caregivers were not blinded to any extent during this 
prospective observational study. However, levels of PCT 
had no influence on the clinical treatment of patients 
as PCT was not routinely determined during the study 
period.
Another limitation of the current study is that the deci-
sion rule and the evaluation of the performance of this 
rule were both determined from the same population of 
patients. In particular, the sensitivity and specificity of 
a procalcitonin cutoff value for delayed complications 
need to be validated in a separate population of patients. 
Moreover, patients developing delayed complications 
showed higher preoperative CRP and PCT levels with a 
higher risk of adverse outcome before surgery. However, 
there was only a low discrimination to predict delayed 
complication after surgery. Although both a large num-
ber of patients and several different surgical procedures 
are included in the current study, confirmation of the 
above results is suggested as part of a multicenter study.
Conclusions
In this single-center, observational cohort study, a sin-
gle measurement of serum PCT level the morning after 
elective cardiac surgery seems to be an independent 
predictor for delayed complications in patients with an 
apparently uneventful postoperative course. Detection of 
such at-risk patients prior to ICU discharge could prob-
ably avoid readmission and ensure adequate monitor-
ing, enabling rapid treatment of emerging complications. 
In conclusion, we think, by monitoring postoperatively, 
PCT is in certain circumstances an interesting concept in 
which the true clinical value of this idea should be evalu-
ated in a large prospective study.
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